Irritable Bowel Syndrome and Functional Dyspepsia: Different Ends of the Same Spectrum of Intestinal Barrier Dysfunction?

Abstract

published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User

miR‐10b‐5p rescues leaky gut linked with gastrointestinal dysmotility and diabetes

“…Dysregulated gut‐brain axis, altered gut motility, altered GI secretion, gut immune dysfunction, microbial dysbiosis, presence and degree of bile acid malabsorption, impaired glucose homeostasis, insulin resistance, and visceral hypersensitivity have all been attributed to the development of DGBIs, highlighting the heterogeneous nature of these disorders 2,3 . Recent studies have highlighted gut barrier dysfunction as a possible core pathophysiological mechanism linking DGBIs to the diabetic condition 2,5–7 . This is likely mediated through gut microbiota‐induced immune dysfunction, which is extremely prevalent in both conditions 2,8,9 .…”

“… 2 , 3 Recent studies have highlighted gut barrier dysfunction as a possible core pathophysiological mechanism linking DGBIs to the diabetic condition. 2 , 5 , 6 , 7 This is likely mediated through gut microbiota‐induced immune dysfunction, which is extremely prevalent in both conditions. 2 , 8 , 9 Therefore, it is of paramount importance that a treatment for gut barrier dysfunction become clinically available for patients with diabetes and DGBIs.…”

Response to Keszthelyi

“…We appreciate the interest of Dr. Keszthelyi (1) in our study and welcome his thoughtful discussion on potential implications of small intestinal barrier dysfunction in the pathogenesis of both functional dyspepsia (FD) and irritable bowel syndrome (IBS). The symptomatic overlap between these disorders is well documented (2), and recent data also indicate that patients with overlapping FD/IBS suffer more severe symptoms, compared with patients with one of the disorders (3).…”